Nestle to buy Aimmune Therapeutics for $2.6 billion

A pedestrian passes a Nestle SA logo at the Nescafe factory, operated by Nestle SA, in Tutbury, U.K., on Thursday, Aug. 23, 2018.

Simon Dawson | Bloomberg | Getty Images

Nestle said it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own as it adds what it hopes will be a lucrative treatment to its portfolio.

The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement.

The price represents a 174% premium to Aimmune’s closing share price on August 28 of $12.60, said the food giant, which has been gearing its traditional portfolio towards health and wellness products.

Up to 240 million people worldwide suffer from food allergies, peanut allergy being the most common, Nestle said.

In January, Aimmune Therapeutics got approval from the U.S. Food and Drug Administration (FDA) for Palforzia, making it the first medication approved for food allergies in children and teens.

Nestle said the acquisition was expected to add to organic growth in 2021 and to cash earnings by 2022/23.

Source link





HBO Max for Amazon Fire TV launches Nov. 17

(L-R) TNT, TBS, truTV, HBO & HBO Max Content Acquisition EVP Michael Quigley, HBO Max CCO and TNT, TBS, & truTV President Kevin...

Amazon doesn’t have to put Parler back online, says judge

The Parler logo is seen on an Apple iPhone.Jaap Arriens | NurPhoto | Getty ImagesA U.S. judge has refused to order Amazon to...

Inside the shadowy world of Ransomware payouts

Marc BleicherSource: CNBCMarc Bleicher is a hostage negotiator — but he's not trying to rescue human hostages, he's trying to rescue data.Bleicher, managing...

WHO frets Europe’s ICU beds are nearing capacity in some areas

A member of the medical staff treats a patient suffering from the coronavirus disease (COVID-19) at the Intensive Care Unit (ICU) of the...

New Campaign Fights COVID Vaccine Disinformation

Feb. 3, 2021 -- As health care providers work against the clock to administer as...